Business Wire

Starwood Accelerates Growth in Gateway European Cities


From the International Hotel Investment Forum (IHIF) in Berlin, Starwood Hotels & Resorts Worldwide, Inc. (NYSE:HOT) today announced its continued expansion in Europe with a record 18 organic hotel openings in 2015 and over 30 hotels already under development and expected to open in the next five years. Looking ahead, Starwood is launching the Tribute Portfolio brand in France, diversifying its brand footprint in Italy and expanding its mid-market brands in the United Kingdom, The Netherlands, Russia and Turkey.

This Smart News Release features multimedia. View the full release here:

Starwood Hotels & Resorts: 2015-2016 European growth infographic (Graphic: Business Wire)

Starwood Hotels & Resorts: 2015-2016 European growth infographic (Graphic: Business Wire)

In 2015, Starwood further strengthened its lead in the luxury segment with openings including The St. Regis Istanbul and W Amsterdam, as well as four The Luxury Collection hotels in destinations such as Prague, Bodrum and Bratislava. Furthermore, Starwood introduced its new Tribute Portfolio brand, a collection of outstanding independent hotels, to Europe with the Great Northern Hotel in London.

“Our strong growth in Europe was instrumental in Starwood’s record-breaking growth in 2015 as we continue to focus on high-quality portfolio growth in desirable and strategic destinations,” said Simon Turner, President of Global Development for Starwood Hotels & Resorts Worldwide, Inc. “Our growth forecast for Europe is stronger than ever with over 30 hotels set to open across our 10 distinct lifestyle brands by 2020.”

“We maintained a steady transaction pace in 2015 with conversions driving almost 40 percent of new hotel signings across Europe, reflecting strong owner interest in our design-led brands and confidence in Starwood’s powerful global systems,” said Michael Wale, President, Starwood Hotels & Resorts, Europe, Africa and Middle East. “We are on track to open close to 10 hotels in Europe this year, introducing our distinct brands to more new markets, and continue to work with our partners on further investments in our existing Sheraton and Le Méridien hotels.”

2016 Opening Highlights in Europe:

Set inside a 19th century heritage building, W Tel Aviv - Jaffa will bring the cutting-edge W lifestyle to the revitalized ancient port neighborhood of Jaffa, Israel. Following the W brand’s lauded entry into The Netherlands with W Amsterdam, the hotel will unveil its second building with 66 rooms, complementing the existing 172 rooms. On track to reach over 75 W Hotels globally by 2020, the brand recently announced the signing for a W hotel in Madrid which will open in 2018.

In the upper upscale segment, Tribute Portfolio makes a double debut in France in March with Le Metropolitan and Le Dokhan’s, both located in the upmarket 16th Arrondissement of Paris, within easy reach of landmarks such as the Eiffel Tower and Avenue des Champs-Elysées.

The Westin brand has an exciting year ahead with two openings in Europe: The Westin Hamburg, which will offer breath-taking water views from atop the new Elbe Philharmonic Hall on the banks of the river Elbe, and The Westin La Quinta Golf & Spa Resort, a conversion in the famous sun-drenched Golf Valley near Marbella.

Together with its hotel owners, Starwood continues to grow and refresh Le Méridien brand’s European portfolio. Milestone projects this year include: The contemporary lifestyle brand will re-enter Italy by the end of this year with Le Méridien Visconti Rome, which is located in the Prati district near the Vatican, following a conversion and extensive renovation. Furthermore, this year, the brand will complete the renovation of its first and flagship property, Le Méridien Etoile in Paris, alongside the transformation of lobby spaces in Le Méridien hotels in Vienna and Hamburg into lively ‘Le Méridien Hubs.’

Starwood’s largest and most iconic brand Sheraton remains on track to add 150 new Sheraton hotels around the globe by 2020. Echoing the company’s conversion strategy, recent examples include Sheraton Cascais Resort, which became Starwood’s third Sheraton hotel in Portugal when it joined the brand last month, and Sheraton Donnafugata in Sicily, which will welcome guests beginning in May. As part of the Sheraton 2020 plan to solidify Sheraton as a leading global hotel brand of choice, Sheraton Park Lane in London, Sheraton Berlin Grand Hotel Esplanade and Sheraton Paris Airport Hotel & Conference Centre will unveil smart, intuitive and forward-looking design when renovations are finished later this year.

Aloft, Element and Four Points have re-energized the mid-market space and created an unprecedented level of buzz in the development community as they expand across Europe. Keeping up with the rising trend of guests seeking eco-conscious alternatives, Element Hotels introduced its whole-living, sustainable lifestyle to The Netherlands earlier this year with the opening of Element Amsterdam in the vibrant Buitenveldert business hub. Known for its genuine service, stylish comfort and flexible options for developers, Four Points by Sheraton boasts Starwood’s fastest growing pipeline globally. Following its successful entry into Turkey last year, the brand will expand its footprint in the country over the next four years with new signings in Atasehir and Kagithane districts in Istanbul and the coastal city of Izmir. Aloft continues to introduce its passion for live music, vibrant design and innovation across Europe, most recently announcing the Aloft Brighton, which will be the brand’s fourth hotel in the United Kingdom when it opens next year.

# # #

About Starwood Hotels & Resorts Worldwide, Inc.
Starwood Hotels & Resorts Worldwide, Inc. is one of the leading hotel and leisure companies in the world with more than 1,270 properties in some 100 countries and over 180,000 employees at its owned and managed properties. Starwood is a fully integrated owner, operator and franchisor of hotels, resorts and residences under the renowned brands: St. Regis ®, The Luxury Collection ®, W ®, Westin ®, Le Méridien ®, Sheraton ®, Tribute Portfolio™, Four Points ® by Sheraton, Aloft ®, Element ®, along with an expanded partnership with Design Hotels . The Company also boasts one of the industry’s leading loyalty programs, Starwood Preferred Guest (SPG®). Visit for more information and stay connected @starwoodbuzz on Twitter and Instagram and

Contact information

Media Contact:
Carrie Bloom
Starwood Hotels & Resorts

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00Pressemelding

The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements